Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | YAP1 | P46937 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.51 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.51 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660273 | 0.96 | KDM4E (0.64) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL26496169 | 0.94 | KDM4E (0.61) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL3272146 | 0.94 | KDM4E (0.60) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL12723099 | 0.94 | KDM4E (0.60) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL19706814 | 0.94 | KDM4E (0.60) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL3040666 | 0.93 | KDM4E (0.62) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL5351275 | 0.91 | KDM4E (0.62) | KDM4EPKMGRIN2BHTTCYP2D6 | |
| SCHEMBL20782479 | 0.90 | KDM4E (0.58) | KDM4EPKMHTTSTSGPR119 | |
| SCHEMBL2826301 | 0.89 | NAMPT (0.61) | KDM4EPKMHTTCYP2D6STS | |
| SCHEMBL29532829 | 0.88 | GRIN2B (0.67) | GRIN2BHTTCYP2D6CYP2C9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110724142-B | Amide or sulfonamide substituted hydrazine derivatives as JAK kinase inhibitors | 启元生物(杭州)有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-110724142-A | Amide or sulfonamide substituted hydrazine derivatives as JAK kinase inhibitors | 维眸生物科技（上海）有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3225623-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9655904-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2467377-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9126940-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1019052-A4 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6143750-A | NITROGEN HETEROCYCLIC COMPOUNDS AS ENZYME INHIBITORS, FOR PROSTATE PROBLEMS AND MUSCLE RELAXANTS | MERCK & CO., INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-1019052-A1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998057640-A1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | KDM4E 333/4885PKM 2756/4885GRIN2B 240/4885 |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | KDM4E 925/4885PKM 2493/4885GRIN2B 225/4885 |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | KDM4E 2371/4885PKM 1716/4885GRIN2B 98/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | KDM4E 2372/4885PKM 3800/4885GRIN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.